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Abstract
Background: Lung cancer is the leading cause of cancer death in men and women in the United
States and Western Europe. Over 160,000 Americans die of this disease every year. The five-year
survival rate is 15% – significantly lower than that of other major cancers. Early detection is a key
factor in increasing lung cancer patient survival. DNA hypermethylation is recognized as an
important mechanism for tumor suppressor gene inactivation in cancer and could yield powerful
biomarkers for early detection of lung cancer. Here we focused on developing DNA methylation
markers for squamous cell carcinoma of the lung. Using the sensitive, high-throughput DNA
methylation analysis technique MethyLight, we examined the methylation profile of 42 loci in a
collection of 45 squamous cell lung cancer samples and adjacent non-tumor lung tissues from the
same patients.
Results: We identified 22 loci showing significantly higher DNA methylation levels in tumor tissue
than adjacent non-tumor lung. Of these, eight showed highly significant hypermethylation in tumor
tissue (p < 0.0001): GDNF, MTHFR, OPCML, TNFRSF25, TCF21, PAX8, PTPRN2 and PITX2.
Used in combination on our specimen collection, this eight-locus panel showed 95.6% sensitivity
and specificity.
Conclusion: We have identified 22 DNA methylation markers for squamous cell lung cancer,
several of which have not previously been reported to be methylated in any type of human cancer.
The top eight markers show great promise as a sensitive and specific DNA methylation marker
panel for squamous cell lung cancer.
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Background
Cancer is responsible for one in four deaths in the US,
making it the second most common cause of death [1].
Lung cancer is the leading cancer killer in men and
women.
Over 160,000 Americans will die of this disease in 2007.
In men, lung cancer accounts for 31% of cancer deaths,
killing more men than leukemia and prostate, colorectal,
and pancreatic cancer combined. In women, lung cancer
accounts for 27% of all cancer deaths, taking as many lives
as breast and colorectal cancer combined [1]. The overall
five-year survival rate of lung cancer patients is 15%, sig-
nificantly lower than that of patients with prostate cancer
(99.9%), breast cancer (88.5%) or colon cancer (64.1%)
[1]. This rate increases dramatically to greater than 50%
when lung cancer is diagnosed at an early stage. However,
only 14–16% of cases are detected early [1].
In contrast to breast, colon, and prostate cancer, no rou-
tine screening method for early detection of lung cancer
exists. Methods based on imaging (chest X-ray, low dose
spiral computed tomography (LDSCT), autofluorescence
bronchoscopy (AFB)), and sputum cytology have been
tested, however, none have proven ideal. Screening via
chest X-ray is not sufficiently sensitive [2], and trials dem-
onstrated that its use in high risk populations showed no
decrease in mortality [3]. LDSCT screening can detect a
number of stage I lung cancers, with survival at 10 years
reported as high as 88% [4]. However, the possibility of
lead-time bias and the high false positive rate [5] limit the
utility of this screening modality. These false positive tests
frequently lead to invasive procedures to remove lesions
that later prove to be benign [6]. In addition, LDSCT
appears to favor detection of peripheral lesions, being less
effective at detecting small pre-invasive/micro-invasive
lesions in the central airways [7]. Its effects on reducing
lung cancer mortality remain in question [8]. Autofluores-
cence bronchoscopy (AFB) also has a high false positive
rate [9,10], and preferentially detects centrally located
cancers. Screening by sputum cytology can detect a
number of aspymptomatic cases, but it has not been
shown to decrease lung cancer mortality [11]. Studies
using molecular marker techniques on sputum samples
appear promising [12].
Given the poor five-year survival rates and limitations of
current screening techniques, it is clear that improved
methods for early detection of lung cancer are needed.
One strategy is to develop sensitive and specific molecular
markers that distinguish cancer type and subtype, that are
detectable in 'remote' patient media (e.g. blood, sputum)
by non-invasive/minimally invasive means, and that can
be assayed using a quantitative approach.
DNA methylation has emerged as a prime source of
potential cancer-specific biomarkers. In cancer, despite
global DNA hypomethylation, many genes become
hypermethylated. Typically this occurs in CpG rich
regions called CpG islands at/near gene promoters. Meth-
ylation often results in the silencing of tumor suppressor
or growth regulatory genes [13]. Such cancer-specific
hypermethylation results in differential DNA methylation
profiles between tumor and non-tumor tissues, which can
be exploited to distinguish the two, allowing DNA meth-
ylation to serve as a cancer-specific molecular marker.
Using bisulfite treatment, which embeds methylation
information in the DNA sequence, coupled with a sensi-
tive and quantitative real-time PCR-based assay (Methy-
Light), hypermethylated CpGs form stable, easily
amplifiable, and readily available biomarkers [14]. As no
one locus can be expected to detect all cancers of a partic-
ular type, reactions for multiple loci can be easily com-
bined into panels of markers, increasing the potential to
detect lung cancer in a highly sensitive and specific man-
ner. Because our end goal is a non-invasive lung cancer
detection method using DNA methylation markers, it is
worth noting that DNA hypermethylation has been
detected in remote patient media such as sputum, blood
[15] and bronchoalveolar lavage (BAL) [16] from lung
cancer patients.
Lung cancer is divided clinically into two major subtypes
– the rapidly progressing small cell lung cancer (SCLC),
and the more common non-small cell lung cancer
(NSCLC). As NSCLC accounts for > 85% of all lung cancer
cases, and is less aggressive than SCLC, there is a greater
chance for early detection, resulting in increased patient
survival. NSCLC is divided into four major histological
subtypes: adenocarcinoma (AD), squamous cell carci-
noma (SQ), large cell carcinoma and others (carcinoids,
neuroendocrine cancers, etc). A comparison of SQ and AD
of the lung shows differences in DNA hypermethylation
profiles [17-19], in expression of therapeutic targets [20],
in the mutational and polymorphic spectra [21,22] and in
gene expression profiles [23]. The region of the lung in
which these tumors usually occur also differs, with AD
typically located at the periphery and SQ arising near the
central airways. Given the distinct nature of SQ and AD, it
is to be expected that different molecular markers would
need to be developed to sensitively detect these two types
of lung cancer. We have recently identified a panel of DNA
methylation markers for lung adenocarcinoma [24]. Here
we focus on the development of molecular markers for
squamous cell lung cancer.
SQ accounts for 25 – 35% of all lung cancer cases in the
United States [25]. Our goal was to identify a panel of
DNA markers that are frequently and highly methylated
in SQ lung tumors when compared to non-tumor lung.Molecular Cancer 2008, 7:62 http://www.molecular-cancer.com/content/7/1/62
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Such a panel may be used for non-invasive/minimally
invasive and potentially subtype-specific early detection
of SQ lung cancer. We envision that in the future, detec-
tion of DNA methylation markers in remote media
(blood, sputum, bronchoalveolar lavage) might comple-
ment less specific imaging-based lung cancer screening
tests, and if sensitivity and specificity are high enough,
might eventually be directly applied to the screening of
high risk populations.
Results
In an effort to develop sensitive and specific molecular
markers for squamous cell carcinoma (SQ) of the lung,
the methylation status of 42 candidate loci was examined
in a collection of 45 tumors and histologically normal
adjacent non-tumor lung samples from the same patients.
These 42 loci were identified in a pre-screen examination
of the methylation status of 304 MethyLight reactions on
cell lines and a small number of tumors distinct from the
ones used in this study (data not shown). As our aim was
to identify novel high penetrance markers for lung SQ,
many loci previously reported as methylated in NSCLC/
SQ were not included in our study due to their lower
methylation frequency. In five of the 42 loci (HRAS,
MGMT, MTHFR, PAX8 and SLC38A4), the region exam-
ined is not in a CpG island. In our pre-screen, multiple
reactions in and around the CpG islands of these loci were
tested and the chosen reactions showed the highest meth-
ylation in cancer. Paired histologically normal adjacent
lung tissue samples, derived from a separate non-cancer
block of the lung cancer patients, were used as control
samples. Thus, our control tissue matched tumor tissue
fully with respect to most variables, including environ-
mental exposures, age, gender, ethnicity and genetic back-
ground. The use of paired control tissue from lung cancer
patients, which may show higher background methyla-
tion, ensures the identification of markers that are hyper-
methylated in a cancer-specific  manner. MethyLight
provides a quantitative measure for methylation at each
locus; the percentage of methylated reference (PMR) value
reflects the level of DNA methylation at the locus exam-
ined compared to in vitro methylated control DNA.
We observed a high methylation frequency (the fraction
of samples showing any methylation) for all 42 loci in
both the tumors and the adjacent non-tumor tissues taken
from the same patient (Figure 1, Table 1). The DNA meth-
ylation in histologically normal adjacent non-tumor lung
is likely due, on the one hand, to the sensitivity of Methy-
Light, and on the other, to age and/or environmental
exposure, and has been observed in other studies [26-28].
We examined the statistical significance of differences in
DNA methylation levels in tumor versus  adjacent non-
tumor tissue using the PMR as a continuous variable. Out
of the 42 loci studied, 13 were previously reported to be
methylated in NSCLC. Hence, a marker from these 13 was
considered statistically significant if it attained the 0.05
level of significance without correction for multiple test-
ing. A marker from the remaining 29 targets was declared
statistically significant if it exceeded the 5% false-discov-
ery rate threshold defined using the Benjamini and Hoch-
berg [29] approach. Overall, twenty-five of the 42 loci
examined showed a statistically significant difference
(highlighted in italics in Table 1). Three markers –
DIRAS3, MGMT, and HRAS – showed statistically signifi-
cant hypermethylation in non-tumor  tissue. The impor-
tance of this suggested loss of methylation in the tumors
was not further explored here, as we are focused on iden-
tifying positive methylation markers for SQ of the lung.
The phenomenon could be of interest for future studies.
The remaining 22 loci were found to be statistically signif-
icantly hypermethylated in the tumors (Table 1). This is
the first report of methylation in any cancer for five loci
(CPVL, HOXC9, PAX8, PTPRN2, and SLC38A4), flagging
these loci as potential novel cancer markers. Eight loci
(GDNF, MTHFR, OPCML, TNFRSF25, TCF21, PAX8,
PTPRN2, and PITX2) showed highly statistically signifi-
cant differences with p-values <0.0001.
Potential biomarkers should be effective in all patients
regardless of cancer stage, age, gender or ethnicity. We
examined DNA methylation levels in tumors vs. adjacent
non-tumor tissue in relation to tumor stage. Because the
number of cases was not very large, we grouped stage IA
and IB cases together (six IA and twenty-five IB), and
stages II and III (no IIA, seven IIB and five IIIA). Each of
the eight highly significant loci showed higher DNA
methylation levels in tumors vs. adjacent non-tumor lung
in both early (stage I; n = 31, p-value range = 1 × 10-7 -
0.0041) and advanced (stage II/III; n = 12, p-value range
= 6 × 10-5 - 0.0194) lung cancer patients. When analyzing
each stage (IA, IB, IIB and IIIA) independently, the two
most significant markers (GDNF and MTHFR) showed
significantly higher DNA methylation levels in tumor vs.
adjacent non-tumor in every stage, despite the modest
number of cases. Comparison of DNA methylation levels
for the top eight markers in early vs. advanced cancers
showed no significant differences between the methyla-
tion levels in these tumors, reinforcing the idea that these
markers are not stage-specific. This is important, since
effective DNA methylation markers for SQ lung cancer
must function on every stage of cancer, but particularly on
early stage tumors.
We also examined methylation in tumors in relation to
age. HOXC9 showed higher levels of DNA methylation in
patients under the median age (70: p = 0.021) and TCF21
showed increased DNA methylation in females (p =
0.047). However, if a multiple comparisons correction
were applied, these differences would not be significant.Molecular Cancer 2008, 7:62 http://www.molecular-cancer.com/content/7/1/62
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DNA methylation of PAX8 appeared higher in males (p =
0.001; significant even with application of a multiple
comparison threshold), a factor that might require con-
sideration if it were to be developed for clinical use. As our
population is primarily Caucasian, we were not able to
examine DNA methylation levels in relation to ethnicity.
Studies are in progress in a larger more ethnically diverse
population, to examine the possible relationship of DNA
methylation to ethnicity.
To provide more insight into the distribution of DNA
methylation levels in the tumor and non-tumor samples,
we plotted the distribution of PMR values for tumor and
non-tumor tissues for the eight most highly significant
loci (Figure 2). These plots illustrate differences in the
nature of these markers that are not evident from the p-
values. For example, GDNF appears to promise substan-
tial specificity and sensitivity due to frequently highly ele-
vated DNA methylation of this locus in tumor tissues. A
similar pattern is seen in MTHFR,  OPCML, and
TNFRSF25. For TCF21,  PTPRN2, and PITX2, the DNA
methylation levels of tumor tissues show a wider distribu-
tion and more overlap with non-tumor samples. The
PAX8 DNA methylation values were tightly clustered, and
while the difference is highly statistically significant (p = 9
× 10-6), the fold-difference is small, indicating that this
marker may not be as useful in the clinical setting.
The utility of clinical markers is often evaluated by gener-
ating a receiver operating characteristic (ROC) curve, in
which sensitivity versus 1-specificity at all possible cutoff
values is plotted. Ultimately, such ROC curves will be gen-
Schematic representation of DNA methylation levels of 42 loci in 45 tumor and adjacent non-tumor squamous cell lung cancer  cases Figure 1
Schematic representation of DNA methylation levels of 42 loci in 45 tumor and adjacent non-tumor squamous cell lung cancer 
cases. Black indicates high methylation levels (≥ median PMR of all, tumor and non-tumor, positive samples). Grey indicates low 
methylation (< median of the positive PMR values), and white indicates no detectable methylation.
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erated based on methylation values detected in remote
media. However, here we used ROC curves based on the
tumor and non-tumor PMR values to provide an early
indication of the potential of the top eight loci as cancer-
specific markers. The area under the curve (AUC), an indi-
cator of marker performance, ranged from a modest 0.75
for PITX2 to a much better 0.9 for GDNF (Figure 3). The
sensitivity and specificity values for each of the eight top
loci were individually calculated using the present tumor
collection in a five-fold cross validation (Table 2). The
Table 1: Statistical analysis of differences in methylation levels between tumor and adjacent non-tumor tissues
Tumor Adjacent Non-Tumor
Gene Namea Methylation
Frequencyb
Median
PMRc
Methylation
Frequencyb
Median
PMRc
p-valued MC
Corr.e
GDNF 95% 67.11 95% 3.29 5.0E-11 0.0017
MTHFRf 100% 56.51 100% 25.95 2.0E-10 *
OPCMLg 95% 19.49 98% 5.80 1.0E-09 *
TNFRSF25 98% 50.52 93% 25.89 2.0E-07 *
TCF21 93% 60.64 88% 11.17 3.0E-07 *
PAX8f 100% 83.90 100% 69.49 9.0E-06 0.0034
PTPRN2 80% 35.60 58% 4.02 1.0E-05 0.0052
PITX2 93% 19.37 95% 1.50 3.0E-05 0.0069
MT1G 95% 1.89 93% 0.59 0.0001 0.0086
PENK 93% 14.30 95% 6.82 0.0002 0.0103
GP1BB 98% 59.52 100% 42.68 0.0009 *
MGMTf 100% 26.73 98% 33.96 0.0009 *
SLC38A4f 56% 6.00 31% 0.00 0.0010 0.0121
SFRP2 98% 10.19 91% 2.67 0.0038 *
RARRES1 60% 9.27 47% 0.71 0.0048 0.0138
DIRAS3 100% 57.25 100% 63.92 0.0074 *
NEUROG1 37% 3.03 17% 0.08 0.0079 0.0155
WDR33 31% 0.34 9% 0.20 0.0089 0.0172
TFAP2A 46% 5.68 20% 10.00 0.0092 0.0190
SFRP1 91% 1.63 98% 0.56 0.0124 *
CYP1B1 58% 3.53 40% 0.41 0.0143 *
HOXC9 66% 10.62 60% 0.48 0.0157 0.0207
ABCB1 100% 27.07 100% 24.33 0.0193 0.0224
HRASf 100% 82.08 100% 90.01 0.0215 0.0241
GRIN2B 44% 28.03 31% 1.26 0.0235 0.0259
CACNA1G 93% 0.74 95% 0.44 0.0282 0.0276
HIC1 98% 33.81 100% 23.52 0.0315 0.0293
CPVL 66% 1.65 53% 0.33 0.0739 0.0310
SEZ6L 89% 5.08 95% 3.51 0.0745 0.0328
NEUROD1 44% 9.97 33% 0.70 0.0748 0.0345
CCND2 98% 1.74 96% 1.18 0.0827 0.0362
MINT1 98% 3.18 98% 2.49 0.0879 0.0379
DLEC 55% 19.39 64% 0.17 0.1169 *
RNR1 100% 43.28 100% 31.91 0.1930 0.0397
BLT1 98% 28.01 100% 25.63 0.2420 0.0414
ONECUT2 98% 17.23 100% 14.29 0.3369 *
PLAGL1 100% 45.72 100% 50.38 0.3747 0.0431
GATM 26% 11.95 69% 0.10 0.4462 0.0448
CDX1 98% 46.96 100% 44.40 0.7469 0.0466
TWIST1 66% 1.98 86% 1.07 0.7578 0.0483
TMEFF2 100% 11.54 100% 11.82 0.7591 *
RPA3 49% 0.24 49% 0.16 0.8863 0.0500
a Human Genome Organization nomenclature. Loci showing a statistically significant difference in methylation between tumor and non-tumor tissue 
are highlighted in italics. The top eight loci are noted in bold. Loci are ranked in order of ascending p-value. b Percentage of samples with positive 
methylation value. c Median percent methylated reference calculated from positive methylation values. d p-value calculated by Wilcoxon signed rank 
test. e To minimize the risk of false discovery, a false-discovery rate threshold using the Benjamini and Hochberg (1995) approach was applied to all 
loci not previously found to be methylated in squamous cell lung cancer (see methods). f This reaction is not targeted to a CpG Island g This primer/
probe set shares homology with the CpG island of the adjacent HNT gene, which appears to have arisen via gene duplication. * Denotes loci 
previously reported to be methylated in lung cancer tumor samplesMolecular Cancer 2008, 7:62 http://www.molecular-cancer.com/content/7/1/62
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quantitative marker values were dichotomized at a level
that would minimize the classification error. Sensitivity
ranged from 58–89% and specificity from 69–100%.
While measurements for several individual markers look
promising, it is unrealistic to expect detection of all cases
of a particular type of cancer using a single biomarker.
Thus, our goal is to develop a panel of DNA methylation
markers that, used in combination, can sensitively and
specifically detect lung SQ. To assess the performance of
combinations of our markers in the identification of
tumors, we fit a random forest classifier to the data set,
using 90 samples and 42 variables. Using bootstrap sam-
ples of the data, we grew a forest of 30,000 trees. Splits
were determined using a random sample of five variables
and trees were grown until there was only one observation
in each leaf. When the 42 loci were ranked using the ran-
dom forests classifier, the top four loci were the same as
when the data was ranked by p-value or AUC value, and
the order of the ranking is the same for these top four in
all three groups (data not shown). Using all 42 loci in
combination, we observed 97.7% sensitivity and 97.7%
specificity. While this is encouraging, 42 loci are too many
to test in a clinical setting. Trimming the panel down to
just the top eight loci resulted in 95.6% sensitivity and
specificity. Further restricting our analysis to the four most
highly ranked loci maintained sensitivity at 95.6% while
specificity dropped to 93.3%.
Discussion
Thirteen of the 42 loci examined here were previously
reported to be methylated in lung cancer tumor samples.
Consistent with the literature, eight loci (MTHFR,
OPCML, TNFRSF25, TCF21, SFRP2, SFRP1, CYP1B1,
GPIBB, DLEC and ONECUT2) [17,24,30-39] are hyper-
methylated in tumor tissue in our study. Indeed, MTHFR,
Distribution of PMR values for the eight most significant loci (as ranked by p-value) Figure 2
Distribution of PMR values for the eight most significant loci (as ranked by p-value). In each panel, PMR values (indicated by 
black dots) for tumor (T) are on the left and adjacent non-tumor lung (AdjNTL) on the right. Grey bars represent the median 
PMR values for tumor and normal tissues.Molecular Cancer 2008, 7:62 http://www.molecular-cancer.com/content/7/1/62
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OPCML, TNFRSF25 and TCF21 show highly statistically
significant differences (p < 1 × 10-6) between tumor and
adjacent non-tumor tissues in our study. The results for
three loci are in contrast with the published literature.
MGMT, DIRAS3 (previously described as ARHI) and
TMEFF2  (previously described as HPP1) have been
reported to be hypermethylated in lung cancer
[17,18,28,33-36,40-45]. We found that MGMT  and
DIRAS3 were statistically significantly more highly meth-
ylated in adjacent non-tumor than in SQ samples, while
for TMEFF2, we observed almost no difference in methyl-
ation levels between tumor and non-tumor tissue (Table
1). The differences between our results and the published
literature may be due to a variety of reasons, including
Receiver Operating Characteristic (ROC) curves for the eight most significant DNA methylation markers (as ranked by p- value), using the current collection of tumor and adjacent non-tumor samples Figure 3
Receiver Operating Characteristic (ROC) curves for the eight most significant DNA methylation markers (as ranked by p-
value), using the current collection of tumor and adjacent non-tumor samples.
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Table 2: AUC, Sensitivity & Specificity Analysis
5-fold cross validation
Locus AUC Sensitivity Specificity
GDNF 0.90 0.82 0.98
MTHFR 0.89 0.89 0.82
OPCML 0.87 0.76 0.89
TNFRSF25 0.82 0.76 0.91
TCF21 0.82 0.62 0.91
PAX8 0.77 0.64 0.69
PTPRN2 0.76 0.58 0.89
PITX2 0.75 0.60 1.00Molecular Cancer 2008, 7:62 http://www.molecular-cancer.com/content/7/1/62
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technical differences (such as the use of the quantitative
MethyLight versus qualitative methylation specific PCR, or
the less sensitive CpG island microarrays), the sampling
of a different region of the gene, differences in the lung
cancer histologies studied (many studies contain a mix of
NSCLC samples), and ethnic/racial differences in the
patient populations studied. In the case of MGMT we sam-
pled regions in and out of the CpG island in our pre-
screen, and the region outside of the CpG island looked
more promising, and was therefore tested. Thus, the
primer/probe set we used differs from what has been pub-
lished in the literature.
When examining the function of the 22 statistically signif-
icant potential markers for SQ, four major functional cat-
egories emerged. Eight loci encode proteins involved in
signaling and growth regulation, seven loci encode tran-
scription factors, four loci encode proteins with metabolic
function, and three loci belong to no particular group
(Table 3). Our strongest potential biomarkers, the eight
most statistically significantly hypermethylated loci, are
scattered across the first three of these groups. Because our
focus is development of DNA methylation markers, our
primary concern is consistent methylation of a particular
locus, not whether the associated gene is actually silenced
by methylation. Hence, genes in which the consistently
hypermethylated locus is outside of the CpG island can
serve as markers (e.g. HRAS, MGMT, MTHFR, PAX8,
SLC38A4), even though the DNA methylation may not be
of functional significance. While we have not determined
whether the genes for our eight top markers are silenced,
there is published evidence for the inactivation of some of
these genes in lung cancer. For others, their expression in
cancer has not yet been investigated, and might be worth
examining in future, more mechanistic, studies. As six of
the top eight loci show potentially functionally relevant
DNA hypermethylation in tumors, we will discuss what is
known about their role in cancer development.
OPCML, TNFRSF25 and  TCF21  have been previously
reported to be hypermethylated in lung cancer [30-32]
and based on their function, methylation-induced silenc-
ing could favor tumor growth. Opioid binding protein/
cell adhesion molecule (OPCML) is an opioid receptor
and is involved in cell-cell adhesion. It binds opioid pep-
tides (e.g. enkephalin) and causes apoptosis of lung can-
cer cell lines, indicating it functions as a tumor suppressor
gene. This inhibition was reversed by nicotine [46], which
may be of particular interest in lung cancer pathogenesis.
It is of note that PENK, which encodes the precursor pep-
tide of the OPCML ligand enkephalin, was also found to
be significantly hypermethylated in tumor tissue in our
Table 3: Putative biological role of the 22 statistically significantly hypermethylated loci
Functional 
Categories
Gene 
Symbola
Gene Nameb Gene Functionb
Signaling GDNF glial cell derived neurotrophic factor Growth factor
GP1BB glycoprotein I b, beta polypeptide Platelet membrane receptor
OPCML opioid binding protein/cell adhesion molecule-like Cell adhesion molecule
PENK proenkephalin Opioid peptide precursor
PTPRN2 protein tyrosine phosphatase, receptor type, N polypeptide 2 Phoshatase
SFRP1 secreted frizzled-related protein 1 Wnt Signaling modulator
SFRP2 secreted frizzled-related protein 2 Wnt signalling modulator
TNFRSF25 tumor necrosis factor receptor superfamily, member 25 Cell surface receptor
Transcription Factor HOXC9 homeobox C9 Transcription factor
NEUROD1 neurogenic differentiation 1 Transcription factor
NEUROG1 neurogenin 1 Transcription factor
PAX8 paired box gene – 8 Transcription factor
PITX2 paired-like homeodomain transcription factor 2 Transcription factor
TFAP2A transcription factor AP 2 alpha Transcription Factor
TCF21 transcription factor 21 Transcription factor
Metabolism CYP1B1 cytochrome p450 family 1, subfamily B, polypeptide 1 Liver metabolism
MT1G metallothionein 1G Heavy metal binding
MTHFR 5,10 methylenetetrahydrofolate reductase (NADPH) Methyl group metabolism
SLC38A4 solute carrier family 38, member 4 Amino acid transporter
Other ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 Drug efflux pump
RARRES1 retinoic acid receptor responder 1 Unclear
WDR33 WD repeat domain 33 Unclear
a Gene symbol is the Human Genome Organization nomenclature. b Gene Name and Function as listed per [63].Molecular Cancer 2008, 7:62 http://www.molecular-cancer.com/content/7/1/62
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studies. This might suggest methylation-induced silencing
of a tumor suppressor pathway. We recently reported
OPCML as highly methylated in lung adenocarcinoma,
[24] indicating that it is a potential AD/SQ lung cancer
biomarker.
Tumor necrosis factor receptor superfamily member 25
(TNFRSF25) has been shown to be methylated in bladder
cancer, and very recently methylation in lung SQ was
reported [31,47]. As this receptor mediates apoptosis,
methylation-induced silencing may facilitate evasion of
cell death – a key step in cancer growth. The transcription
factor TCF21 has been reported to be more highly meth-
ylated in lung cancer tissue than non-tumor adjacent lung,
and overexpression in mouse xenografts results in a reduc-
tion in tumor size and weight [32]. This implies a tumor
suppressor function for TCF21, therefore tumor-associ-
ated promoter DNA methylation, and possibly transcrip-
tional silencing, are not surprising.
For other genes, such as PITX2, PAX8 and PTPRN2, the
biological consequences of DNA methylation remain a
question. Functionally, it is unclear how PITX2 silencing
would contribute to lung cancer growth. This member of
the paired-like homeodomain transcription factor family
functions in left-right asymmetry in development [48],
but has no described function in adult lung. However,
cancer-related methylation is reported in other tissues in
which the gene has no described function, for example, in
acute myeloid leukemia [49], breast cancer [50], and pros-
tate cancer [51]. Interestingly, higher DNA methylation
levels of PITX2 are associated with greater recurrence of
both breast and prostate cancer [50,51]. Whether such a
link exists in lung cancer will require further studies. Pro-
tein tyrosine phosphatase, receptor type, N polypeptide 2
(PTPRN2) is an autoantigen involved in insulin depend-
ent diabetes mellitus [52]. No previous reports of methyl-
ation of PTPRN2 exist, making it a potentially novel
cancer biomarker.
The most intriguing of the identified loci is the top marker
GDNF, encoding glial cell line-derived neurotrophic fac-
tor. GDNF has been reported to be overexpressed in lung
tumor tissue [53] and is silent in normal adult lung [54].
As a ligand for the RET proto-oncogene, GDNF would be
a likely candidate for promoting cancer progression, and
has been proposed to do so in pancreatic cancer [55].
DNA methylation of this locus would seem contradictory.
However, the high DNA methylation we report is at pro-
moter 2 (located at the intron 1/exon 2 boundary of
GDNF), a promoter that has been shown to have low
activity [56]. Indeed, in our preliminary studies, a primer
designed against the primary promoter of GDNF showed
no hypermethylation (data not shown). It may be possi-
ble that DNA methylation at the downstream promoter is
somehow related to the transcriptional activity from the
upstream promoter. Given the fact that GDNF is, to our
knowledge, the strongest candidate DNA methylation
marker for lung SQ identified to date, this issue would be
worth investigating further.
While the top eight markers identified in this study show
highly significant DNA hypermethylation in cancer, it will
of course be important to validate these markers in an
independent collection of samples. Such studies are in
progress using a specimen collection balanced for gender
and the major ethnic groups in the United States.
Conclusion
Our primary goal is to find sensitive and specific biomar-
kers for the early detection of lung cancer. Differences in
the biology and treatment of different lung cancer histo-
logical subtypes warrant the development of markers for
each cancer subtype. We have recently reported a panel of
DNA methylation markers for lung adenocarcinoma [24].
Here we report the identification of promising DNA
methylation markers for squamous cell lung cancer. Sta-
tistical analysis of the difference in DNA methylation lev-
els between SQ tumor and adjacent non-tumor lung tissue
identified 25 statistically significant loci. Of these, three
are potential negative DNA methylation markers (more
methylated in adjacent non-tumor tissues), while 22 are
potential positive DNA methylation markers. Of the 22
loci, we focused on those eight that were ranked most sig-
nificantly hypermethylated in the cancer versuspaired
non-cancer samples by p-value and ROC curves. These
eight loci are significantly hypermethylated in both early
(stage I) and more advanced cancers. Two of those eight
loci (PAX8, PTPRN2) have never been reported to be
hypermethylated in human cancer specimens, and thus
constitute promising new candidate cancer markers. To
our knowledge, the eight-locus panel consisting of GDNF,
MTHFR, OPCML, TNFRSF25, TCF21, PAX8, PTPRN2 and
PITX2, constitutes the highest sensitivity and specificity
DNA methylation marker panel for lung SQ reported to
date. Following its validation on a separate set of tumor
and non-tumor lung samples, the next step will be to
examine the DNA methylation of these loci in remote
media (such as blood, sputum, bronchoalveolar lavage)
from lung cancer patients and control non-cancer cases. In
conjunction with our work on AD lung cancer and ongo-
ing studies of other NSCLC subtypes, we hope to develop
a panel of markers for the sensitive and specific detection
of non-small cell lung cancer that would also identify the
histological subtype. The further development of DNA
methylation markers promises to be important not only
for diagnostics, but also for prognostication, the ability to
follow response to therapy, and guidance in the choice of
treatment.Molecular Cancer 2008, 7:62 http://www.molecular-cancer.com/content/7/1/62
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Methods
Tissue samples and DNA extraction
Samples were collected from the Los Angeles County Hos-
pital archives, the Norris Comprehensive Cancer Center
archives and the National Disease Research Interchange
(NDRI). Study subjects included 21 males and 22 females
ranging in age from 45 – 84 at time of diagnosis (median
age: 70 years old). Age and gender information was miss-
ing for 2 patients. The study population was primarily
Caucasian, with 35 Caucasians, 2 African Americans and
race unknown for 8 patients. Information as to tumor
stage was available for 43 of the 45 patients. TNM status
was either listed in the pathology report, or discerned
from the report using the International System for Staging
Lung Cancer [57]. This information was used to assign
tumor stage. There were 6 stage IA, 25 stage IB, 7 stage IIB
and 5 stage IIIA patients. Sections were cut from separate,
histologically verified, tumor and adjacent non-tumor
paraffin blocks. A 5 μm slide was haematoxylin & eosin
(H&E) stained and coverslipped for histological confir-
mation of tumor histological type, and presence or
absence of tumor, by an expert lung pathologist (MNK).
Five adjacent 10 μm slides were cut, H&E stained, and
tumor or non-tumor material was manually microdis-
sected. DNA was extracted via proteinase K digestion [58].
Briefly, cells were lysed in a solution containing 100 mM
Tris-HCl (pH 8.0), 10 mM EDTA (pH 8.0), 1 mg/mL pro-
teinase K, and 0.05 mg/mL tRNA and incubated at 50°C
overnight. The DNA was bisulfite converted as previously
described [59]. All studies were institutionally approved
by the University of Southern California Institutional
Review Board (IRB# HS-016041, HS-06-00447), and the
identities of patients were not made available to labora-
tory investigators.
Methylation analysis
DNA methylation analysis was done by MethyLight as
previously described [59]. A pre-screen methylation anal-
ysis using cell lines and five sets of paired SQ/non-tumor
adjacent lung (distinct from the samples used in this
study) were used to screen over 300 DNA methylation
loci, and led to the identification of 42 loci of interest,
which were evaluated in this study. The primer and probe
sequences are described in the supplemental data [see
additional file 1]. In addition to primer and probe sets
designed specifically for the locus of interest, two internal
reference primer and probe sets directed against collagen
and ALU repeats were included in the analysis to normal-
ize for input DNA [60,61]. The percentage methylated ref-
erence (PMR) compares the level of methylation in the
sample to in vitro methylated control DNA. It is calculated
by dividing the GENE:reference ratio of a sample by the
GENE:reference ratio of M. SssI-treated in vitro methylated
human DNA and multiplying by 100 [59]. PMRs were
individually calculated using the collagen and ALU con-
trols and then averaged.
Statistical analysis
Using PMR as a continuous variable, methylation levels of
tumor samples were compared to adjacent non-tumor
lung by means of the Wilcoxon signed rank test. The large
number of loci analyzed increases the potential for false
discovery. To counteract this risk, a multiple comparisons
threshold was set and applied to those loci for which no
previous data demonstrated their methylation in SQ of
the lung at the time of analysis (Table 1, last column;
[29]). To examine whether tumor-specific hypermethyla-
tion was seen in early as well as later stages of SQ lung can-
cer, methylation levels in tumor and adjacent non-tumor
tissue were compared for "early" (stages IA and IB, n = 31)
and more advanced cancers (stages II and III, n = 12), as
well as for each individual stage (IA, IB, IIB and IIIA) using
the Wilcoxon test. The same test was applied to the com-
parison of methylation levels in tumor samples between
the early and advanced cancers. Associations with gender
and age were tested using the Wilcoxon test to compare
methylation levels within the tumor sample collection
only. As an indicator of the potential utility of methyla-
tion of these loci as a marker for cancer, Receiver Operat-
ing Characteristic (ROC) curves were calculated for each
of our top markers, using the PMR values for the tumor
and adjacent non-tumor lung specimens. All statistical
tests were two-sided. Statistical tests were carried out using
JMP (v 5.0.1a, SAS Institute Inc, NC).
To determine which combinations of markers would be
most effective to correctly identify tumor vs. non-tumor
samples, we fit a random forest classifier to the data set,
using the R programming language (v 2.5; [62]) and 90
samples and 42 variables. Using bootstrap samples of the
data, we grew a forest of 30,000 trees. Splits were deter-
mined using a random sample of five variables and trees
were grown until there was only one observation in each
leaf. We determined error rates using the observations that
were not used to generate the trees. For each observation,
its outcome was predicted by having the majority vote
from the trees that were generated without the original
data point in their bootstrap sample. These predicted val-
ues were compared against the true tissue type to estimate
prediction error.
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